Interaction Checker

Vitamin E interactions

High-dose vitamin E can inhibit platelet aggregation and add to the bleeding risk of blood thinners.

Vitamin E has 18 documented interactions across the FDA labels and fact sheets we index: 0 major, 15 moderate, 3 minor, and 0 where a label reports no significant interaction. Each entry below quotes the sentence behind it. This vitamin and mineral page is a starting point, not a verdict for your situation.

Moderate interactions (15)

  • ApixabananticoagulantModerate

    Vitamin E can inhibit platelet aggregation and vitamin K-dependent clotting, increasing bleeding risk with anticoagulant and antiplatelet drugs. (NIH Office of Dietary Supplements, Vitamin E)

  • AspirinNSAIDModerate

    Vitamin E can inhibit platelet aggregation and vitamin K-dependent clotting, increasing bleeding risk with anticoagulant and antiplatelet drugs. (NIH Office of Dietary Supplements, Vitamin E)

  • Aspirin and dipyridamoleantiplatelet agentModerate

    Vitamin E can inhibit platelet aggregation and vitamin K-dependent clotting, increasing bleeding risk with anticoagulant and antiplatelet drugs. (NIH Office of Dietary Supplements, Vitamin E)

  • Cilostazolantiplatelet agentModerate

    Vitamin E can inhibit platelet aggregation and vitamin K-dependent clotting, increasing bleeding risk with anticoagulant and antiplatelet drugs. (NIH Office of Dietary Supplements, Vitamin E)

  • Clopidogrelantiplatelet agentModerate

    Vitamin E can inhibit platelet aggregation and vitamin K-dependent clotting, increasing bleeding risk with anticoagulant and antiplatelet drugs. (NIH Office of Dietary Supplements, Vitamin E)

  • DabigatrananticoagulantModerate

    Vitamin E can inhibit platelet aggregation and vitamin K-dependent clotting, increasing bleeding risk with anticoagulant and antiplatelet drugs. (NIH Office of Dietary Supplements, Vitamin E)

  • Dipyridamoleantiplatelet agentModerate

    Vitamin E can inhibit platelet aggregation and vitamin K-dependent clotting, increasing bleeding risk with anticoagulant and antiplatelet drugs. (NIH Office of Dietary Supplements, Vitamin E)

  • EdoxabananticoagulantModerate

    Vitamin E can inhibit platelet aggregation and vitamin K-dependent clotting, increasing bleeding risk with anticoagulant and antiplatelet drugs. (NIH Office of Dietary Supplements, Vitamin E)

  • EnoxaparinanticoagulantModerate

    Vitamin E can inhibit platelet aggregation and vitamin K-dependent clotting, increasing bleeding risk with anticoagulant and antiplatelet drugs. (NIH Office of Dietary Supplements, Vitamin E)

  • FondaparinuxanticoagulantModerate

    Vitamin E can inhibit platelet aggregation and vitamin K-dependent clotting, increasing bleeding risk with anticoagulant and antiplatelet drugs. (NIH Office of Dietary Supplements, Vitamin E)

  • HeparinanticoagulantModerate

    Vitamin E can inhibit platelet aggregation and vitamin K-dependent clotting, increasing bleeding risk with anticoagulant and antiplatelet drugs. (NIH Office of Dietary Supplements, Vitamin E)

  • Prasugrelantiplatelet agentModerate

    Vitamin E can inhibit platelet aggregation and vitamin K-dependent clotting, increasing bleeding risk with anticoagulant and antiplatelet drugs. (NIH Office of Dietary Supplements, Vitamin E)

  • RivaroxabananticoagulantModerate

    Vitamin E can inhibit platelet aggregation and vitamin K-dependent clotting, increasing bleeding risk with anticoagulant and antiplatelet drugs. (NIH Office of Dietary Supplements, Vitamin E)

  • Ticagrelorantiplatelet agentModerate

    Vitamin E can inhibit platelet aggregation and vitamin K-dependent clotting, increasing bleeding risk with anticoagulant and antiplatelet drugs. (NIH Office of Dietary Supplements, Vitamin E)

  • WarfarinanticoagulantModerate

    Vitamin E can inhibit platelet aggregation and vitamin K-dependent clotting, increasing bleeding risk with anticoagulant and antiplatelet drugs. (NIH Office of Dietary Supplements, Vitamin E)

Minor mentions (3)

  • NiacinMinor

    Antioxidant combinations including vitamin E blunted the HDL-raising effect of simvastatin plus niacin in a clinical study. (NIH Office of Dietary Supplements, Vitamin E)

  • OrlistatMinor

    ORLISTAT inhibited absorption of a vitamin E acetate supplement. (Orlistat label, Drug interactions)

  • SimvastatinstatinMinor

    Antioxidant combinations including vitamin E blunted the HDL-raising effect of simvastatin plus niacin in a clinical study. (NIH Office of Dietary Supplements, Vitamin E)

Check Vitamin E against everything you take. Add your full list; every pair is checked at once.

Open in the checker

Not medical advice. Severity reflects the label's wording, not your circumstances. A "major" flag can be routine under supervision and a "minor" one can matter at high doses. Ask a pharmacist.